Company Encyclopedia
View More
name
Palvella Therapeutics
PVLA.US
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
1.912 T
PVLA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Palvella Therapeutics COO Kathleen Goin Sells Shares

    Reporter NameGoin KathleenRelationshipChief Operating Officer, 10% OwnerTypeSellAmount$415,022SEC FilingForm 4Kathleen Goin, Chief Operating Officer and 10% owner at Palvella Therapeutics, sold 4,302 shares of common stock on December 17, 2025, at a weighted average price of $96.472 per share, totaling $415,022. Following the transaction, Goin no longer directly owns any common stock in the company.SEC Filing: PALVELLA THERAPEUTICS, INC. [ PVLA ] - Form 4 - Dec. 19, 2025

    TradingView·
    US
    PVLA
    +3.63%
    TradingView·
    US
    PVLA
    +3.63%

    The $100 Club - Were You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…?

    Several stocks, including ABIVAX, Nutex Health, Cidara Therapeutics, Palvella Therapeutics, Celcuity, and Belite Bio, have recently crossed the $100 mark, marking significant financial milestones. These companies have shown substantial growth due to successful clinical trials, acquisitions, and financial turnarounds. The article highlights their progress and future plans, such as drug applications and ongoing trials, contributing to their stock price increases.

    rttnews·
    US
    CDTX
    +0.20%
    US
    BLTE
    +0.94%
    US
    NUTX
    +3.05%
    rttnews·
    US
    CDTX
    +0.20%
    US
    BLTE
    +0.94%
    US
    NUTX
    +3.05%

    BUZZ-Palvella Therapeutics climbs after Truist raises PT

    Shares of Palvella Therapeuticsrose 6.14% to $94.45 after Truist raised its price target to $190 from $105, citing positive results from a proof of concept study for Qtorin gel. All 15 brokerages rate the stock as a 'buy' or 'strong buy,' with a median price target of $190. PVLA has increased 641.5% year-to-date.

    Reuters·
    US
    PVLA
    +3.63%
    Reuters·
    US
    PVLA
    +3.63%

    Palvella Therapeutics (NASDAQ:PVLA) Trading Up 6.6% on Analyst Upgrade

    Palvella Therapeutics (NASDAQ:PVLA) shares rose 6.6% after Canaccord Genuity Group raised its price target from $148 to $204, maintaining a buy rating. Other analysts also increased their target prices, contributing to the stock's upward movement. Institutional investors have adjusted their stakes, with 40.11% of the stock owned by them. The company reported a quarterly EPS of ($1.03), missing estimates. Palvella Therapeutics focuses on therapies for rare genetic skin diseases.

    Market Beat·
    US
    PVLA
    +3.63%
    Market Beat·
    US
    PVLA
    +3.63%

    Palvella: FDA Grants Fast Track Designation For QTORIN Rapamycin In Angiokeratomas

    Palvella Therapeutics announced that the FDA granted Fast Track Designation to QTORIN rapamycin for treating angiokeratomas. This designation may lead to accelerated approval and priority review if criteria are met. Palvella plans to discuss a Phase 2 study with the FDA in 2026, aiming to initiate the study in the second half of the year.

    rttnews·
    US
    PVLA
    +3.63%
    rttnews·
    US
    PVLA
    +3.63%
    © 2025 Longbridge｜Disclaimer